Single-photon emission computed tomography

Preclinical Imaging Global Market Report 2023: Sector to Reach $3.93 Billion by 2030 at a 6.51% CAGR

Retrieved on: 
星期一, 一月 23, 2023
Photon, Reagent, Modality, Drug discovery, Research, Private, Single-photon emission computed tomography, Strategic management, Market share analysis, Use, Magnetic resonance imaging, Positron emission tomography, Pathfinder, Institute for Governance of Private and Public Organizations, Magnetic particle imaging, COVID-19, Application, MRI, Business Growth Fund, User (computing), Value, Optical flow, Customer support, Medical imaging, Pharmaceutical industry, Retail

The FPNV Positioning Matrix evaluates and categorizes vendors in the Global Preclinical Imaging Market.

Key Points: 
  • The FPNV Positioning Matrix evaluates and categorizes vendors in the Global Preclinical Imaging Market.
  • The Global Preclinical Imaging Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.
  • What is the market share of the leading vendors in the Global Preclinical Imaging Market?
  • What modes and strategic moves are considered suitable for entering the Global Preclinical Imaging Market?

Preclinical Imaging Global Market Report 2023: Increasing Adaptation of Diagnostic Imaging Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
星期四, 一月 19, 2023
Health Technology, Health, Clinical Trials, Photon, Value, Private, Modality, Customer support, Use, COVID-19, Optical flow, Positron emission tomography, Reagent, Market share analysis, Pathfinder, User (computing), Strategic management, Application, Magnetic particle imaging, Single-photon emission computed tomography, Magnetic resonance imaging, MRI, Drug discovery, Business Growth Fund, Research, Institute for Governance of Private and Public Organizations, Medical imaging, Fine chemical, Retail

The FPNV Positioning Matrix evaluates and categorizes vendors in the Global Preclinical Imaging Market.

Key Points: 
  • The FPNV Positioning Matrix evaluates and categorizes vendors in the Global Preclinical Imaging Market.
  • The Global Preclinical Imaging Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.
  • What is the market share of the leading vendors in the Global Preclinical Imaging Market?
  • What modes and strategic moves are considered suitable for entering the Global Preclinical Imaging Market?

Small Animal Imaging (In-Vivo) Global Market Report 2022: Ukraine-Russia War Impact

Retrieved on: 
星期四, 十一月 24, 2022
Photon, Single-photon emission computed tomography, Animal, Research report, Disease, Development, Vega, Pathology, Tissue, COVID-19, CT scan, Optical flow, Transducer, Life Technologies, Economy, GDP, Organization, Rigaku, CT, LI-COR Biosciences, Biomarker, PerkinElmer, Growth, General Electric, Acquisition, OECD, Promega, Bruker, PET, Miltenyi Biotec, Area studies, Agilent Technologies, Maternity leave and the Organisation for Economic Co-operation and Development, Milab, HIV disease progression rates, Medical imaging, Healthcare, New England Biolabs, SPECT

The small animal imaging (in-vivo) market is expected to grow to $3.38 billion in 2026 at a compound annual growth rate (CAGR) of 10.5%.

Key Points: 
  • The small animal imaging (in-vivo) market is expected to grow to $3.38 billion in 2026 at a compound annual growth rate (CAGR) of 10.5%.
  • The small animal imaging (in-vivo) market consists of sales of small animal imaging (in-vivo) products by entities (organizations, sole traders, and partnerships) that are used to observe, define, and quantify normal and pathologic processes in living animal organs and tissues non-invasively.
  • Technological advancement is a key trend gaining popularity in the small animal imaging (in-vivo) market.Major companies operating in the small animal imaging (in vivo) market are focused on technological advancement to strengthen their position.
  • The small animal imaging(in-vivo)market research report is one of a series of new reports that provides small animal imaging(in-vivo)market statistics, including small animal imaging(in-vivo)industry global market size, regional shares, competitors with a small animal imaging(in-vivo)market share, detailed small animal imaging(in-vivo)market segments, market trends and opportunities, and any further data you may need to thrive in the small animal imaging(in-vivo)industry.

World Nuclear Imaging Agents Market Report 2022: Regulatory and Reimbursements, Procedures, & Forecasts 2015-2030 Featuring Cardinal Health, GE Healthcare, Novartis, Bracco Imaging, DuPont de Nemours - ResearchAndMarkets.com

Retrieved on: 
星期二, 九月 20, 2022
Health, Other Health, Photon, Single-photon emission computed tomography, COVID-19, Epidemiology, Country, PET/MRI, Diagnosis, Nuclear, PET/CT, ASP, Review, CMO, Industry, Strategic planning, Segment, Volume, Investment, PET, GlobalData, Region, Medical imaging, SPECT, SWOT, Cancer, Positron emission tomography, SPECT/CT, SWOT analysis, Renewable energy, Retail, Public relations, Forecast

The model discusses in detail the impact of COVID-19 on Nuclear Imaging Agents market for the year 2020 and beyond.

Key Points: 
  • The model discusses in detail the impact of COVID-19 on Nuclear Imaging Agents market for the year 2020 and beyond.
  • Nuclear Imaging is a noninvasive medical technique which uses radioactive tracers (generally F-18 Fluorodeoxyglucose) to assess and diagnose bodily functions and diseases.
  • Nuclear Imaging Agent's have been classified into Positron Emission Tomography (PET) Systems and Single Photon Emission Computed Tomography (SPECT) Systems.
  • Track device sales in the global and country-specific Nuclear Imaging Agents market from 2015-2030.

With 5.41% CAGR, Molecular Imaging Market Size to Hit USD 7.3 Billion by 2032 | Future Market Insights

Retrieved on: 
星期三, 九月 14, 2022
Photon, Siemens, Single-photon emission computed tomography, Conditional sentence, Siemens Healthineers, Adoption, Health, Cardiology, Time, Molecular imaging, Gynaecology, Hospital, Philips, Prevalence, Functional neurologic disorder, Acquisition, Growth, Biotelemetry, Isotopia Festival, Industry, Deep learning, Canon Medical Systems Corporation, Lung cancer, PET, Degenerative disease, Cancer, Lung nodule, Bruker, Technology, FMI, Lists of diseases, Market, CT, Diagnosis, SPECT, Health care, Awareness, Lists of countries and territories, Globe, Radiology, Positron emission tomography, CAGR, Agriculture, Medical imaging, Fine chemical, Renewable energy, Software

NEWARK, Del., Sept. 14, 2022 /PRNewswire/ -- The global molecular imaging market is anticipated to value at US$ 7.3 Billion while expanding at a CAGR of 5.41% during the forecast period of 2022-2032. The growth of the market can be attributed to the increasing incidences of chronic illness across the globe.

Key Points: 
  • Growing Adoption of AI-Based Technology in the Healthcare Sector to Expand the Molecular Imaging Market at a CAGR of 5.41% by 2032.
  • In Europe, the molecular imaging market is expected to display a CAGR of 4% during the forecast period.
  • Key Takeaways from the Market Study:
    The global molecular imaging market is expected to secure US$ 4.309 Billion in 2022.
  • Future Market Insights,in its new offering, presents an unbiased analysis of the global molecular imaging market, presenting a historical analysis from 2017 to 2021 and forecast statistics for the period of 2022-2032.

GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease

Retrieved on: 
星期二, 九月 13, 2022
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Clinical Trials, Photon, Single-photon emission computed tomography, Half-life, American Society of Nuclear Cardiology, St. Luke's Hospital, Development, Molecular imaging, Thomas Edison, Twitter, NYSE, MPI, Phase, Research, Hospital, LinkedIn, Society, News, Coronary artery disease, Patient, Intelligence, PET, LNTH, 18F, Luke the Evangelist, Myocardial perfusion imaging, Research and development, Cardiology, Doctor of Philosophy, CAD, Ecosystem, NASDAQ, Death, Neurology, SPECT, GE Healthcare, Congress, Multimedia, ASNC, FACC, Positron emission tomography, Medical imaging, Pharmaceutical industry, MD, Facebook

GE Healthcare and Lantheus Holdings Inc (NASDAQ: LNTH) have announced that the recent Phase III clinical trial of their investigational radiotracer, [18F]flurpiridaz, has met its co-primary endpoints of exceeding a 60 percent threshold for both sensitivity and specificity for detecting Coronary Artery Disease (CAD).

Key Points: 
  • GE Healthcare and Lantheus Holdings Inc (NASDAQ: LNTH) have announced that the recent Phase III clinical trial of their investigational radiotracer, [18F]flurpiridaz, has met its co-primary endpoints of exceeding a 60 percent threshold for both sensitivity and specificity for detecting Coronary Artery Disease (CAD).
  • Dr. Francois Tranquart, MD, PhD, Global Head of Clinical Development for GE Healthcare Pharmaceutical Diagnostics, Research and Development, said: The positive Phase III trial results are a key step towards future approval of Flurpiridaz (18F) Injection as a potential new cardiac PET agent which could improve the detection of coronary artery disease.
  • This is another example of GE Healthcare investing in our portfolio of Molecular Imaging products to help improve diagnostic accuracy and patient outcomes.
  • GE Healthcare is the $17.7 billion healthcare business of GE (NYSE: GE).

GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease

Retrieved on: 
星期二, 九月 13, 2022
Photon, Single-photon emission computed tomography, Half-life, NORTH, American Society of Nuclear Cardiology, St. Luke's Hospital, Development, Molecular imaging, Thomas Edison, Twitter, NYSE, MPI, Phase, Research, Hospital, LinkedIn, Society, News, Coronary artery disease, Program, Patient, Intelligence, PET, LNTH, 18F, Myocardial perfusion imaging, Luke the Evangelist, Research and development, Cardiology, Doctor of Philosophy, CAD, Ecosystem, NASDAQ, Death, Neurology, SPECT, GLOBE, GE Healthcare, Congress, ASNC, FACC, Positron emission tomography, Medical imaging, Pharmaceutical industry, MD, Facebook

Dr. Francois Tranquart, MD, PhD, Global Head of Clinical Development for GE Healthcare Pharmaceutical Diagnostics, Research and Development, said: The positive Phase III trial results are a key step towards future approval of Flurpiridaz (18F) Injection as a potential new cardiac PET agent which could improve the detection of coronary artery disease.

Key Points: 
  • Dr. Francois Tranquart, MD, PhD, Global Head of Clinical Development for GE Healthcare Pharmaceutical Diagnostics, Research and Development, said: The positive Phase III trial results are a key step towards future approval of Flurpiridaz (18F) Injection as a potential new cardiac PET agent which could improve the detection of coronary artery disease.
  • This is another example of GE Healthcare investing in our portfolio of Molecular Imaging products to help improve diagnostic accuracy and patient outcomes.
  • GE Healthcare has led the funding and development of [18F]flurpiridaz, and, if the imaging agent is approved, will have global commercialization rights.
  • GE Healthcare is the $17.7 billion healthcare business of GE (NYSE: GE).

Global Single Photon Emission Computed Tomography (SPECT) Market Trajectory & Analytics, 2022-2026: United States Dominates the Global SPECT Market, Asia-Pacific to Register Faster Growth - ResearchAndMarkets.com

Retrieved on: 
星期三, 八月 24, 2022
Health Technology, Health, Medical Devices, Photon, Inflammation, COVID-19, Single-photon emission computed tomography, 3D, Cancer, Alzheimer's disease, Research, Pain scale, Radioactive decay, Seizure, Awareness, Infarction, SPECT, Heart, Calibration, Blood, Diagnosis, Radiopharmaceutical, Stroke, Nuclear medicine, Coronary artery disease, 2D, Gamma, Prevalence, CAGR, Stand-alone, Neoplasm, Growth, Cardiology, Medical imaging

The "Single Photon Emission Computed Tomography (SPECT) - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Single Photon Emission Computed Tomography (SPECT) - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Functioning of internal organs can be analyzed with greater assurance and accuracy with SPECT imaging.
  • This segment currently accounts for a 43.8% share of the global Single Photon Emission Computed Tomography (SPECT) market.
  • There are also a few alternatives to SPECT for instance, scintigraphy, increasing popularity of which can limit market growth.

Philochem and Bracco Imaging Announce a Collaboration on the Development of a Small Molecule for Diagnostic or Medical Imaging Applications

Retrieved on: 
星期二, 三月 22, 2022
Disease, Cytokine, Diagnosis, Jaden Philogene-Bidace, Board, Magnetic resonance imaging, Nuclear medicine, Cancer, Interventional radiology, CEO, Technology, Google Images, Single-photon emission computed tomography, Solution, 3D ultrasound, CEUS, Magnetic resonance, MRI, Acquisition, Patient, Cardiac catheterization, Antibody, Medical imaging, Fine chemical

Bracco and Philochem will pioneer the development of cutting-edge technologies for the discovery and optimization of small molecule ligands that enable unprecedented specificity and sensitivity for the imaging of solid tumors.

Key Points: 
  • Bracco and Philochem will pioneer the development of cutting-edge technologies for the discovery and optimization of small molecule ligands that enable unprecedented specificity and sensitivity for the imaging of solid tumors.
  • This new collaboration will focus on the development and commercialization of a small molecule for imaging applications, which promises to improve the diagnosis, staging and monitoring of response-to-treatment for cancer patients.
  • We are very excited about this collaboration with Philochem, a leader in the discovery and development of novel pharmaceutical and biopharmaceutical products.
  • Bracco Imaging S.p.A., part of the Bracco Group, is a worldleading diagnostic imaging provider.

2021 HospeTrack Hospital Intelligence Report for Turkey - ResearchAndMarkets.com

Retrieved on: 
星期四, 八月 5, 2021
Health, Hospitals, Mesothelioma, Magnetic resonance imaging, Cancer, ZIP Code, Hospital, Population, Incidence, Asbestos, University, Government, Pleural cavity, Patient, Single-photon emission computed tomography, Nuclear medicine, Breast, Sarayköy Nuclear Research and Training Center, Life expectancy, Bulgarian–American Joint Military Facilities, PET, Death, Radiology, Private, CT, State, Lung cancer, Medical imaging, Health insurance

According to this new HospeTrack Hospital Intelligence for Turkey, opportunities for medical device manufacturers in the immediate term are evident in the secondary care sector for radiology equipment, and tertiary care for nuclear medicine equipment respectively.

Key Points: 
  • According to this new HospeTrack Hospital Intelligence for Turkey, opportunities for medical device manufacturers in the immediate term are evident in the secondary care sector for radiology equipment, and tertiary care for nuclear medicine equipment respectively.
  • HospeTrack Hospital Intelligence for Turkey, Guidance & Hospital Segmentation
    3.
  • HospeTrack Hospital Intelligence for Turkey, Installed Base Pivot Analysis
    5.
  • HospeTrack Hospital Intelligence for Turkey, IB Base File